Drug intelligence / Profile preview

ASC51

Development stage: Preclinical
Lead developer: Ascletis Pharma
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Oral

Overview

ASC51 is an orally bioavailable, once-daily small molecule degrader targeting Signal Transducer and Activator of Transcription 6 (STAT6). Developed by Ascletis Pharma, the drug is designed to treat various immune-mediated diseases. STAT6 is a key transcription factor in the IL-4/IL-13 signaling pathway, which plays a central role in Type 2 inflammation. By degrading STAT6 rather than just inhibiting it, ASC51 aims to provide more potent and durable suppression of inflammatory responses compared to traditional inhibitors. It is currently in the discovery phase.

Targets

STAT6 (Signal Transducer and Activator of Transcription 6)

Beyond the preview

Go deeper on ASC51.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASC51.

Explore the full profile